Abstract
Cannabinoids, the active ingredients in marijuana, have dramatic effects on various organ systems. They exert their effects through two receptor types: CB1, primarily located in the brain, and CB2, primarily located in the immune system. Vertebrates also produce their own cannabinoid-like substances called endocannabinoids, including anandamide and 2-arachidonoylglyceral. Interestingly, some effects of endocannabinoids could not be explained by the signals through either CB1 or CB2. Recently, the orphan G protein-coupled receptor 55 (GPR55) was proposed to be an atypical cannabinoid receptor. In this issue of Oncogene, two groups demonstrated that GPR55 is expressed in various cancer types in an aggressiveness-related manner, suggesting a novel cancer biomarker and a potential therapeutic target.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma
Histochemistry and Cell Biology Open Access 29 July 2021
-
Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism
Scientific Reports Open Access 13 February 2017
-
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells
BMC Cancer Open Access 13 July 2016
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alexander A, Smith PF, Rosengren RJ . (2009). Cannabinoids in the treatment of cancer. Cancer Lett 285: 6–12.
Andradas C, Caffarel MM, Pérez-Gómez E, Salazar M, Lorente M, Velasco G et al. (2010). The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene (e-pub ahead of print 6 September 2010; doi:10.1038/onc.2010.402).
Das SK, Paria BC, Chakraborty I, Dey SK . (1995). Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci USA 92: 4332–4336.
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949.
Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ et al. (2010). A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160: 762–771.
Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K . (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105: 2699–2704.
Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83–90.
Oesch S, Gertsch J . (2009). Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies? J Pharm Pharmacol 61: 839–853.
Oka S, Kimura S, Toshida T, Ota R, Yamashita A, Sugiura T . (2010). Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147: 671–678.
Piñeiro R, Maffucci T, Falasca M . (2010). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene (e-pub ahead of print 13 September 2010; doi:10.1038/onc.2010.417).
Sharir H, Abood ME . (2010). Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126: 301–313.
Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP et al. (2008). The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139: 225–236.
Sugiura T, Kodaka T, Kondo S, Tonegawa T, Nakane S, Kishimoto S et al. (1996). 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 229: 58–64.
Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ et al. (2009). The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 106: 16511–16516.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Hu, G., Ren, G. & Shi, Y. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene 30, 139–141 (2011). https://doi.org/10.1038/onc.2010.502
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.502
This article is cited by
-
Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma
Histochemistry and Cell Biology (2021)
-
Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression
Journal of Cancer Research and Clinical Oncology (2018)
-
Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism
Scientific Reports (2017)
-
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells
BMC Cancer (2016)
-
Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer
Molecular Cancer (2015)